The effect of hesperidin administration on glucose / insulin metabolism

Completed

• Conditions: metabolic syndrome; obesity; overweight; 10018424

• Registration Number: NL-OMON42312
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2015-10-23
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 53

Inclusion Criteria

Men/women, healthy human beings, age 18-65 and two of following criteria:
*Waist circumference: men > 102 cm / women > 88 cm
*Triglycerides: * 1.7 mmol/l
*HDL-cholesterol: men * 1.0 mmol/l / women * 1.3 mmol/l
*Systolic blood pressure: * 130 mmHg or diastolic blood pressure: * 85 mmHg
*Fasted serum glucose * 6.1 mmol/L

Exclusion Criteria

Type 2 diabetes mellitus; gastroenterological diseases or abdominal surgery; cardiovascular diseases; cancer; liver or kidney malfunction; disease with life expectancy shorter than 5 years; self-admitted HIV-positive status; abuse of products such as alcohol (>20 alcoholic consumptions per week) or drugs; smoking; plans to lose weight or following a hypocaloric diet; weight gain or loss > 3 kg in previous 3 months; use of medication interfering with endpoints; use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets, or in alternative medicine; hormone replacement therapy; use of antibiotics in the 90 days prior to the start of he study; known pregnancy; lactation; history of side effects towards intake of flavonoids or citrus fruits; administration of investigational drugs or participating in any scientific intervention study which may interfere with this study (to be decided by principal investigator) in the 180 days prior to the study; blood donation within 3 months before study period; failure to comply prohibited intake of hesperidin containing food products during study period

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of this study is to evaluate the efficacy of Cordiart* on<br /><br>glucose/insulin metabolism, as assessed by OGTT measurements, after 12 weeks of<br /><br>administration.</p><br>